$13.3M cash, zero debt, runway into 2028. NOCISCAN scan volume +89% year-over-year for three consecutive record quarters. CLARITY pivotal trial on schedule. Revenue is minimal; the clinical milestones in 2026 are the story.
Aclarion built a scanner that tells surgeons which disc in your back is causing your chronic pain; something no other diagnostic can do reliably. Surgeons are using it in increasing volume: scans grew 89% year-over-year. The company has $13.3M in cash, zero debt, and a runway into 2028. Revenue is basically nothing right now because they're still proving the technology through clinical trials. The pivotal trial results come in 2026. The cash covers the wait.
Watch for Q2 2026 CLARITY trial early interim data announcement and Q4 2026 public interim data. Also watch quarterly scan volume as the operational leading indicator; sustained 50%+ growth confirms clinical adoption is real.